Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
coli, which became better at surviving a mixture of animal antimicrobial peptides in vitro and more effective at killing infected caterpillars. Not all resistance to colistin and some other antibiotics is due to the presence of resistance genes. Heteroresistance, the phenomenon wherein apparently genetically identical microbes exhibit a range of resistance to an antibiotic, has been observed in some species of Enterobacter since at least 2016 and was observed in some strains of Klebsiella pneumoniae in 2017–2018. In some cases this phenomenon has significant clinical consequences.
== Measurement == These different definitions have true physical meaning because different techniques in physical polymer chemistry often measure just one of them. For instance, osmometry measures number average molar mass and small-angle laser light scattering measures mass average molar mass. Mv is obtained from viscosimetry and Mz by sedimentation in an analytical ultra-centrifuge. The quantity a in the expression for the viscosity average molar mass varies from 0.5 to 0.8 and depends on the interaction between solvent and polymer in a dilute solution. In a typical distribution curve, the average values are related to each other as follows:
== History == Vosilasarm was developed by Radius Health in 2010. It was first described in the literature in 2011 in a paper detailing its design, synthesis, and preclinical characterization in vitro and in rats and monkeys. It was stated in this paper that phase 1 clinical studies of vosilasarm for treatment of severe weight loss due to cancer cachexia were being prepared. However, these studies were never completed or published and development for this indication was discontinued. Subsequently, vosilasarm was repurposed for the treatment of breast cancer.
The concept of Portal came from Narbacular Drop, a student project from the DigiPen Institute of Technology. The game included the aspects of placing portals on any flat surfaces and using them to maneuver around levels. Several Valve employees, attending a DigiPen career fair, saw Narbacular Drop and offered the entire team jobs at Valve almost immediately to help expand on their idea. Valve originally saw Portal as an experimental game to be included with its upcoming compilation, The Orange Box, alongside its release of Half-Life 2: Episode Two and Team Fortress 2. To give the game character, a minimal story, tied loosely with the Half-Life world, was written by Valve's Erik Wolpaw. He needed a character to guide the player through the game, coming onto a polite but humorous artificial intelligence, which would ultimately become the character of GLaDOS. Portal's release with The Orange Box received near-universal praise, with the standalone game earning an aggregate Metacritic rating of 90 out of 100. With success of the game, work on an expanded sequel began nearly immediately, expanding the development team from 8 to about 30-40 programmers. Initial ideas for Portal 2 retained the idea of solving puzzles through scientific concepts, but eliminating the use of portals altogether; these versions did not fare well with test audiences nor with Gabe Newell, Valve's president; these ideas were dropped though saved for potential reuse in a different game by Valve.
Sources: en.wikipedia.org
Nicotine dependence pathophysiology in heavy smokers suggests less efficient network architecture in the brain and disruptions in the topological organization of brain networks, with the altered brain network metrics correlated with the duration of cigarette use and the severity of nicotine dependence. Some long-term effects of nicotine may be irreversible because "it is entirely possible that doses of nicotine achieved in the brains of human smokers can damage or kill mHb [medial habenula] neurons that regulate nicotine avoidance behaviors", but more studies are needed to elucidate this underlying mechanism of nicotine-induced degeneration of the mHb-IPn circuit . A 2026 Nature study revealed that nicotine mimics endogenous acetylcholine in the nucleus accumbens, artificially triggering dopamine release to biologically "tag" behaviors as valuable, high-effort achievements regardless of actual difficulty. During active use, this chemical shortcut causes salience dysregulation and "false productivity," as the brain assigns intense reward signals to trivial tasks independent of outcome quality while displacing ambition for a meaningful achievement.
Despite the underlying notion of the lab as a confined space for experts, the term "laboratory" is also increasingly applied to workshop spaces such as Living Labs, Fab Labs, or Hackerspaces, in which people meet to work on societal problems or make prototypes, working collaboratively or sharing resources. This development is inspired by new, participatory approaches to science and innovation and relies on user-centred design methods and concepts like Open innovation or User innovation. One distinctive feature of work in Open Labs is the phenomenon of translation, driven by the different backgrounds and levels of expertise of the people involved.
Diffusion force caused by concentration gradient—all particles including ions diffuse from higher concentration to lower. Electrostatic force caused by electrical potential gradient—cations like protons H+ diffuse down the electrical potential, anions in the opposite direction. These two gradients together can be expressed as an electrochemical gradient, providing energy for abiogenic synthesis. The proton motive force measures the potential energy stored as proton and voltage gradients across a membrane (differences in proton concentration and electrical potential). The surfaces of mineral particles inside deep-ocean hydrothermal vents have catalytic properties similar to those of enzymes, and can create simple organic molecules, such as methanol (CH3OH) and formic, acetic, and pyruvic acids out of the dissolved CO2 in the water, if driven by an applied voltage or by reaction with H2 or H2S. Starting in 1981, researchers proposed that life might have started at hydrothermal vents, that spontaneous chemistry in the Earth's crust driven by rock–water interactions at disequilibrium thermodynamically underpinned life's origin, and that the founding lineages of the archaea and bacteria were H2-dependent autotrophs that used CO2 as their terminal acceptor in energy metabolism. In 2016, Martin suggested that the LUCA "may have depended heavily on the geothermal energy of the vent to survive". That same year, RNA was produced in synthetic alkaline hydrothermal chimneys simulating deep-sea vents. Researchers were able to generate RNA oligomers of up to 4 units in length.
Loose connective tissue is characterized by few fibers and cells, and a relatively large amount of ground substance. Dense connective tissue has a smaller amount of ground substance compared to the fibrous material. The meaning of the term has evolved over time.
Peter S. Tippett (born 1953) is an American physician, researcher, and inventor known for contributions to information security, clinical medicine, and technology. These contributions include the development of the anti-virus program "Corporate Vaccine." Tippett was Vice President of Verizon's Innovations Incubator and Chief Medical Officer for Verizon Enterprise Services from 2009 to 2015. He is currently the Founder and CEO of careMESH Inc.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.